yanikler.co.uk Report : Visit Site

Technical data of the yanikler.co.uk

Geo IP provides you such as latitude, longitude and ISP (Internet Service Provider) etc. informations. Our GeoIP service found where is host yanikler.co.uk. Currently, hosted in Germany and its service provider is Hetzner Online AG .

HTTP Header Analysis

HTTP Header information is a part of HTTP protocol that a user's browser sends to called Apache containing the details of what the browser wants and will accept back from the web server.

DNS

HtmlToText

company company profile leadership supervisory board scientific advisory board partners fsa technologies platforms tcr-t platform dc-platform tabs-platform immune monitoring facility publications abstracts pipeline immunotherapy pipeline other products indications investors & media press releases the medigene share stock id analyst reports capital measures shareholder structure reports & presentations webcasts corporate governance corporate governance report declaration on corporate governance corporate management remuneration directors' dealings directors' holdings articles of association compliance code of conduct whistleblower system events annual general meeting 2018 2017 2016 2015 2014 2013 2012 2011 2010 press photos contact e-mail alert career working at medigene jobs de living immunotherapies we are empowering t cells to effectively fight cancer. immunotherapies show great promise to revolutionize cancer treatment. therefore, we put living t cells - key players in the immune system - at the center of our technology platforms. we are striving to create breakthrough therapies to fundamentally improve the lives of cancer patients. latest news 10/02/2018 07:30:00 medigene participates at four conferences in october show release 09/11/2018 07:30:00 medigene participates at further conferences in september show release 09/06/2018 10:20:00 medigene announces inclusion in sdax show release show all news fighting cancer with cutting-edge technologies the therapeutic potential of human t cells can radically change the future of cancer treatment. medigene uses its proprietary platform technologies to modify t cells for the fight against tumor cells, thereby activating the body’s own immune defense mechanisms. tcr-ts generating large numbers of cancer-specific t cells to recognize and kill cancer cells. more about tcr-ts dcs an entirely new generation of dc vaccines being developed. more about dcs tabs developing monoclonal antibodies to recognize t cells. more about tabs deeply rooted in science our deep scientific expertise is rooted in decades of immunological research by prof. dr. dolores j. schendel and her team. more about our expertise capacity to innovate the cumulated scientific knowledge and experience of our scientists, allied with high-throughput automation technologies, accelerate the discovery and development process for new therapies. more about our innovations growing pipeline our first tcr-t therapy mdg1011 has entered clinical development, augmenting the proprietary clinical-stage dc vaccines. we aim to fill our immunotherpy pipeline of with more natural tcr-ts and prepare them for clinical development. more about our pipeline nimble and efficient at medigene, we combine state-of-the-art science and an entrepreneurial start-up culture within the structures of an established biopharmaceutical company. more about our company mdg1 listed on the frankfurt stock exchange, sdax, wkn: a1x3w > 100 headquartered in munich, germany and with an office in san diego, usa, actually over 100 employees +17% increase in research & development expenses for immunotherapies in 6m 2018, compared to previous year. partner-like medigene has developed several clinical stage drugs, ranging from the research phase to commercialization and product launch onto the market. in cooperation with partners, we intend to become a global leader in the field of t cell immunotherapies. more about our partners “"we made substantial progress in the first half of 2018, having initiated our first t cell receptor (tcr) trial. we also significantly expanded our collaboration with bluebird bio, increasing the number of tcr projects from four to six. the successful completion of a private placement raising eur 32.3 million in gross proceeds leaves us well-positioned to drive forward on our broader drug development plans as we transition from recruitment to treatment within our tcr-t trial." dolores schendel, ceo living immuno­therapies, together our highly qualified scientists are dedicated to working at the forefront of cancer immunotherapies. working closely with our experienced business specialists, they jointly develop highly innovative and effective therapies in order to help patients with severe illnesses. more about career company company profile leadership supervisory board scientific advisory board partners fsa technologies platforms immune monitoring facility publications abstracts pipeline immunotherapy pipeline other products indications investors & media press releases the medigene share reports & presentations corporate governance compliance events annual general meeting press photos contact e-mail alert career working at medigene jobs contact medigene ag lochhamer str. 11 82152 planegg/martinsried directions tel.: +49-89-20 00 33 - 0 fax: +49-89-20 00 33 - 29 20 email medigene(at)medigene.com social media contact email alert imprint privacy disclaimer © medigene ag 2018 all rights reserved.

URL analysis for yanikler.co.uk

https://www.medigene.com/home/technologies/platforms/dc-platform/
https://www.medigene.com/home/technologies/abstracts/
https://www.medigene.com/home/company/scientific-advisory-board/
https://www.medigene.com/home/pipeline/immunotherapy-pipeline/
https://www.medigene.com/home/company/fsa/
https://www.medigene.com/home/investors-media/the-medigene-share/capital-measures/
https://www.medigene.com/home/pipeline/other-products/
https://www.medigene.com/home/investors-media/corporate-governance/corporate-management/
https://www.medigene.com/home/company/partners/
https://www.medigene.com/home/investors-media/reports-presentations/webcasts/
https://www.medigene.com/home/investors-media/corporate-governance/directors-holdings/
https://www.medigene.com/home/investors-media/press-photos/
https://www.medigene.com/home/career/working-at-medigene/
https://www.medigene.com/home/investors-media/corporate-governance/articles-of-association/
https://www.medigene.com/home/company/

Whois Information

Whois is a protocol that is access to registering information. You can reach when the website was registered, when it will be expire, what is contact details of the site with the following informations. In a nutshell, it includes these informations;

Error for "yanikler.co.uk".

the WHOIS query quota for 2600:3c03:0000:0000:f03c:91ff:feae:779d has been exceeded
and will be replenished in 6940 seconds

WHOIS lookup made at 00:21:21 07-Sep-2017

--
This WHOIS information is provided for free by Nominet UK the central registry
for .uk domain names. This information and the .uk WHOIS are:

Copyright Nominet UK 1996 - 2017.

You may not access the .uk WHOIS or use any data from it except as permitted
by the terms of use available in full at http://www.nominet.uk/whoisterms,
which includes restrictions on: (A) use of the data for advertising, or its
repackaging, recompilation, redistribution or reuse (B) obscuring, removing
or hiding any or all of this notice and (C) exceeding query rate or volume
limits. The data is provided on an 'as-is' basis and may lag behind the
register. Access may be withdrawn or restricted at any time.

  REFERRER http://www.nominet.org.uk

  REGISTRAR Nominet UK

SERVERS

  SERVER co.uk.whois-servers.net

  ARGS yanikler.co.uk

  PORT 43

  TYPE domain

DISCLAIMER
This WHOIS information is provided for free by Nominet UK the central registry
for .uk domain names. This information and the .uk WHOIS are:
Copyright Nominet UK 1996 - 2017.
You may not access the .uk WHOIS or use any data from it except as permitted
by the terms of use available in full at http://www.nominet.uk/whoisterms,
which includes restrictions on: (A) use of the data for advertising, or its
repackaging, recompilation, redistribution or reuse (B) obscuring, removing
or hiding any or all of this notice and (C) exceeding query rate or volume
limits. The data is provided on an 'as-is' basis and may lag behind the
register. Access may be withdrawn or restricted at any time.

  REGISTERED no

DOMAIN

  NAME yanikler.co.uk

NSERVER

  NS3.AMAN-MEDIA.DE 217.195.32.10

  NS4.AMAN-MEDIA.DE 81.3.2.135

Mistakes

The following list shows you to spelling mistakes possible of the internet users for the website searched .